BlossomHill Therapeutics (NASDAQ:BLSM) Rating Increased to Strong-Buy at Leerink Partners

BlossomHill Therapeutics (NASDAQ:BLSM) was upgraded by Leerink Partners to a “strong-buy” rating in a research note issued on Tuesday, Zacks reports.

BLSM has been the subject of several other reports. JPMorgan Chase & Co. assumed coverage on BlossomHill Therapeutics in a report on Tuesday. They issued an “overweight” rating and a $28.00 price objective for the company. Guggenheim initiated coverage on shares of BlossomHill Therapeutics in a research note on Tuesday. They set a “buy” rating and a $30.00 target price on the stock. Wall Street Zen raised shares of BlossomHill Therapeutics to a “hold” rating in a report on Saturday, August 15th. Lifesci Capital assumed coverage on shares of BlossomHill Therapeutics in a research note on Tuesday. They issued an “outperform” rating and a $32.00 price target for the company. Finally, HC Wainwright initiated coverage on shares of BlossomHill Therapeutics in a report on Tuesday. They set a “buy” rating and a $35.00 price objective for the company. Three investment analysts have rated the stock with a Strong Buy rating and two have issued a Buy rating to the company’s stock. Based on data from MarketBeat.com, BlossomHill Therapeutics presently has an average rating of “Strong Buy” and a consensus price target of $32.20.

BlossomHill Therapeutics Trading Up 3.8%

BLSM stock opened at $18.99 on Tuesday. BlossomHill Therapeutics has a 1-year low of $15.25 and a 1-year high of $20.61.

Insider Buying and Selling

In other news, Director John P. Schmid bought 6,000 shares of the company’s stock in a transaction on Monday, August 10th. The shares were acquired at an average cost of $16.00 per share, with a total value of $96,000.00. Following the completion of the transaction, the director owned 6,000 shares of the company’s stock, valued at approximately $96,000. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Orbimed Advisors Llc purchased 625,000 shares of BlossomHill Therapeutics stock in a transaction dated Monday, August 10th. The shares were acquired at an average cost of $16.00 per share, with a total value of $10,000,000.00. Following the transaction, the director directly owned 2,714,279 shares in the company, valued at approximately $43,428,464. The trade was a 29.91% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have purchased 1,573,900 shares of company stock valued at $25,181,900 in the last 90 days.

BlossomHill Therapeutics Company Profile

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company’s lead clinical programs include BH-30643. BlossomHill Therapeutics Inc is headquartered in San Diego, California.